- TLDR Biotech
- Archive
- Page -118
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | August 19 - 20, 2025
🧬 Saniona hear's sweet Jazz with $42.5M upfront + $992.5M biobucks pre-clinical Kv7.2/Kv7.3 potassium channel activator partnership, biotech has reached a "new normal", Rocket Pharma's capillary leak syndrome gene therapy hold lifted, Xoma buys another "zombie" biotech, Catalent cuts 350 gene therapy manufacturing roles after "unexpected shift in demand from a large customer"
Biotech & Pharma Updates | August 18 - 19, 2025
🧬 BMS, Pfizer, Regeneron signal strong Q2 sales after an oddly weak Q1, Novo Nordisk + BioMedX partner on oral peptide drug delivery tech, Ozempic scores additional label approvals in Canada, Viking Tx shares crater after disappointing Ph2 obesity pill readout, FDA rejects PTC's Friedreich’s ataxia small molecule, CSL cuts 15% of workforce - slashing R&D and considering vaccine subsidiary spin out
Biotech & Pharma Updates | August 17 - 18, 2025
🧬 Kriya's massive $313.3M raise for single-dose gene therapies, Reunion experimental psychedelic delivers positive postpartum results, Merck KGaA's up to $2B partnership with SkyHawk on small molecule RNA-targeting meds, Novo + GoodRx give DTC another change with discounted GLP-1s, Genentech scraps up to $2B cell therapy deal with Adaptive
Biotech & Pharma Updates | August 13 - 14, 2025
🧬 Eli Lilly's $1.3B Superluminal partnership to keep obesity pipeline spry, Trump delays pharma tariffs (but boosts domestic manufacturing), Eli Lilly expands self-pay access to Zepbound via Goodpath partnership, Evotec and TriLink layoffs, Schrödinger cuts investigational CDC7 blocker after two patient deaths
Biotech & Pharma Updates | August 12 - 13, 2025
🧬 Sarepta touts new DMD safety data (no ambulatory deaths), Vor's Sjögren's syndrome disease bet hits late stage trial success in China, Hatteras Venture Partners news $200M biotech/healthtech fund, HopeAI's partners with Mayo Clinical on AI-powered trial design, Treg takes an L as Abata Tx shutters, Generation Bio cuts 90% of staff
Biotech & Pharma Updates | August 11 - 12, 2025
🧬 Summit skips quarterly call as AstraZeneca deal rumors fly, Bayer + Kumquat Biosciences' up to $1.3B KRAS G12D inhibitor deal, Eli Lilly + UK gov launch obesity care access initiative, Insmed scores FDA approval for bronchiectasis therapy, FDA may deny renewed authorization for Pfizer's pediatric COVID vaccine
